---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015746"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:00:27.916543+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Clearside reports Q2 loss of $7.8M, secures $65M non-dilutive financing, OASIS data due Nov

## Summary
- Net loss $7.8M ($0.13/shr) vs $6.1M ($0.11/shr) in Q2 2021; license revenue $384K down from $780K.
- Cash $29.0M at June 30; initial $32.5M royalty payment from HealthCare Royalty extends runway into 2024.
- CLS-AX OASIS Phase 1/2a top-line data for all four cohorts expected November 2022.
- Non-dilutive financing up to $65M: $32.5M initial, $12.5M escrow, $20M milestone upon XIPERE sales targets.
- Appointed Susan L. Coultas, Ph.D., as Chief Clinical Officer; XIPERE J-code effective July 1, 2022.

## SEC filing metadata
- accession: 0000950170-22-015746
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017022015746/0000950170-22-015746-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017022015746/clsd-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015746
- JSON: https://secwatch.observer/filing/0000950170-22-015746.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015746.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.